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Available online at www.sciencedirect.comBiopharmaceuticals are an integral part of modern medicine and
pharmacy. Both, the development and the biotechnological
production of biopharmaceuticals are highly cost-intensive and
require suitable expression systems. In this review we discuss
established and emerging tools for reengineering the
methylotrophic yeast Pichia pastoris for biopharmaceutical
production. Recent advancements of this industrial expression
system through synthetic biology include synthetic promoters to
avoid methanol induction and to fine-tune protein production.
New platform strains and molecular cloning tools as well as in
vivo glycoengineering to produce humanized glycoforms have
made P. pastoris an important host for biopharmaceutical
production.
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Introduction
Biopharmaceuticals are indispensable in modern medi-
cine. The estimated market value is $70 to 80 billion
(depending on the definition) and annual growth rates
between 7 and 15% are expected [1–3]. This is another
major reason for the worldwide focus of pharmacy and
biotechnology on biopharmaceutical development and
production. By definition, the term ‘biopharmaceutical’
refers to recombinant therapeutic proteins and nucleic
acid based products and in the broader sense also to
engineered cell or tissue-based products [2]. Vaccines,
interferons and hormones like insulin, human growth
hormone (hGH) and erythropoietin (EPO) are examples
for protein biopharmaceuticals. Antibodies (including
fragments like Fabs, scFvs and nanobodies) represent
the biggest group of protein biopharmaceuticals [1–3].
Open access under CC BY-NC-ND license.Current Opinion in Biotechnology 2013, 24:1094–1101 Therapeutic proteins are typically produced in mamma-
lian cell lines and Escherichia coli. While bacterial systems
exhibit fast and robust growth in bioreactors using simple
media, mammalian cells resemble their human counter-
parts more closely in terms of typical eukaryotic post
translation modifications (PTMs) like glycosylation [2,4–
6]. However, mammalian cell culture processes are rela-
tively slow, require complex media, and are susceptible
viral contaminations (Table 1).
Using yeasts enables to combine robust growth on simple
media (in large scale bioreactors) with easily achievable
genetic modifications and the introduction of the desired
PTMs [7].
The ‘classic’ yeast Saccharomyces cerevisiae is one of the
best studied eukaryotes and has been used as expression
host for biopharmaceuticals since the early days of genetic
engineering and recombinant protein production [8].
Recently, the first biopharmaceutical produced in the
methylotrophic yeast Pichia pastoris has been approved
by the FDA (Kalbitor by Dyax Corp., a Kallikrein inhibi-
tor) [1]. P. pastoris features all favorable traits of yeasts
mentioned and has successfully been used to produce
high titers of numerous heterologous proteins [7,9,10].
Additionally, P. pastoris is suitable for high cell density
cultivations, reaching more than 150 g dry cell weight per
liter [11] and has high secretory capabilities for heter-
ologous proteins, while secreting only low amounts of
endogenous proteins (Table 1) [12].
In this review we focus on new opportunities for biophar-
maceutical production by reengineered P. pastoris
employing new tools, (semi-) synthetic parts and PTM
pathways (see Figure 1). We also summarized already
published approaches to identify regulatory elements and
to reengineer promoters for bottom-up regulatory circuit
design.
Recent developments in synthetic biology have extended
the toolset of classical genetic engineering [13]. Tailor-
made expression systems have been created by modifying
transcription, translation, PTMs and designing synthetic
regulatory networks [14,15].
Glycoengineering
The majority of therapeutic proteins contain post-transla-
tional modifications, with glycosylation being the most
common and at the same time the most complex PTM
[2].www.sciencedirect.com
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Table 1
Comparison of expression systems used for biopharmaceutical production [4,6,7]
Higher eukaryotes Yeast Escherichia coli
Ease of genetic modifications Moderate Simple Simple
Cultivation Slow growth rates, expensive complex
(or synthetic) media required
Fast and robust growth, defined minimal media Fastest growth, defined
minimal media
Contaminations Risk of viral contaminations, viral
clearance required
Little risks of endotoxins or viral DNAs Endotoxins presence requires
thorough purification, possible
phage infections
Post translational modifications
(PTMs)
Closely resembling human
PTMs; usually mixtures of several
glycoform variants
Most human PTMs achievable, but natural glycosylation
patterns differ from humans, hypermannosylation,
engineered strains can achieve human glycoforms and high
uniformity
Limited set of PTMs, some
human PTMs (e.g. glycosylation)
difficult to achieve
Protein yields and secretory
capacities
High yields, highly efficient
secretion, high specific productivity
High yields, secretory capacities depending on the species High expression capacities,
secretion mostly inefficient,
extensive purification and
downstream processing required
Most commonly used species Mammalian cells Insect cells Pichia pastoris Saccharomyces cerevisiae
Recently approved
biopharmaceuticalsa
32 2 2b 4 17
Additional information and
specific differences between
host species of the
same class
Commonly used cell lines: CHO
(Chinese Hamster Ovary),
BHK (baby hamster kidney),
murine-myeloma-derived
NS0, SP2/0 cell lines [2] and
HEK293
Baculo virus based
systems most
commonly used
for transfection
Easy scale up
Contaminations less
problematic
Mammalianized
glycosylation [5]
Efficient and selective secretion,
often higher protein titers than
S. cerevisiae, for example, [8]
Important eukaryotic model
organism, high molecular- and
cell biological knowledge
Fastest efficient expression
system
Inexpensive
Well established processes
suitable for mass production
Folding problems may lead to
the formation of inclusion
bodies and require expensive
refolding (yet, inclusion
bodies provide a valuable
strategy to achieve high
protein yields and simple
purification)
Inefficient acetate
metabolism may hamper
high cell density cultivation
of some strains
Crabtree negative, high cell
density cultivations
Crabtree positive, leading to
ethanol production
GRAS status
Hypermannosylation is less pronounced in P. pastoris
and critical terminal a-1,3-mannose linkages were not
observed [19], engineered strains providing fully
humanized glycosylation not available for S. cerevisiae
a Data from Walsh [1], time period: January 2006–June 2010, in total 58 biopharmaceuticals have been approved, two biopharmaceuticals produced in transgenic animals were not listed.
b In this number Jetrea by ThromboGenics is included (approved in 2012 and not listed by Walsh [1]).
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Figure 1
Pichia pastoris Biopharmaceuticals
Synthetic biology
Glycoengineering 
Synthetic promoters
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Current synthetic biology approaches to improve biopharmaceutical yields and quality in P. pastoris. Glycoengineered strains provide humanized N-
glycosylation patterns [14,15,16], synthetic promoters allow the fine-tuning of expression levels [41,42,43] and various tools for strain engineering
[47–49,50] and metabolic modeling [55,56,57] are available.Yeasts can perform typical eukaryotic PTMs, but final
glycosylation patterns of yeasts and humans differ signifi-
cantly. Hypermannosylation and terminal a-1,3-mannose
linkages associated with glycoproteins from S. cerevisiae, can
result in poor serum half-life or even immunogenic effects
of therapeutic proteins [2,16]. Thus, there have been
efforts to humanize yeast glycosylation which has been
accomplished in P. pastoris (see [16–18] for reviews). Also
hypermannosylation is less pronounced in P. pastoris and
terminal a-1,3-mannose linkages are not observed [19].
Here, we focus on recent developments of glycoengineer-
ing in P. pastoris and highlight the synthetic biology
approaches and the heterologous and chimeric enzymes
used for this purpose.
Achieving humanized glycosylation in yeast required on
the one hand the elimination of hyperglycosylation by
deleting the appropriate yeast genes, but on the other
hand also the introduction of additional glycosidases and
glycosyltransferases, including missing biosynthetic path-
ways and transporters for sugars not present in yeast, for
example, sialic acid. In the case of galactose, UDP-glu-
cose was converted to UDP-galactose in the Golgi by
providing the respective epimerase activity [16,17].
In addition to simple expression of these genes, correct
spatial positioning along the secretory pathway in the ER
and Golgi is essential, as the sequential activity of one
enzyme produces the substrate for the next. To achieve
the suitable positioning of the required factors along this
cellular assembly line in P. pastoris, synthetic glycobiol-
ogy [20] approaches were used.Current Opinion in Biotechnology 2013, 24:1094–1101 Tailor-made glycosyltransferases and glycosidases with
the desired catalytic properties and localization charac-
teristics were created [19,21–25]. The strategy was based
on the knowledge, that eukaryotic glycosyltransferases
and glycosidases are type II membrane proteins, consist-
ing of an N-terminal cytoplasmic tail, a membrane anchor
domain, a stem region and a C-terminal catalytic domain
(see Figure 2) [20]. The C-terminal catalytic domain is
active independently of the localization conferring N-
terminal part, which is also termed ‘CTS’ (cytoplasmic,
transmembrane, stem). Fusions of catalytic domains to
CTS fragments allowed the creation of semi-synthetic
glycosyltransferases and glycosidases. A combinatorial
library approach paired with a high-throughput screening
was used to create and evaluate these proteins [19,21,22].
Rational design led to similar results [23–25], but even-
tually input from combinatorial libraries was also used
[25].
Notably, the initial publications of the combinatorial
libraries [19,21] contained barely any information on their
composition and how the chimeric glycosyltransferases
were designed. More recently, a comprehensive report
about the catalytic domains, the CTS fragments, and how
they were fused was published [26]. The authors had
not only started from a large set of 33 catalytic domains
from different eukaryotes (e.g. fungi, worm, fruit fly,
mouse, rat, human) and 66 fungal leader sequences,
but also tested fusions of various lengths of both the
catalytic domain and the CTS. Up to 600 variants were
screened for optimal desired activity and localization
along the generated artificial glycosylation pathways in
P. pastoris (see Figure 2).www.sciencedirect.com
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Figure 2
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Design strategies to create semi-synthetic glycosyltransferases and glycosidases for glycoengineering. On the left side, the general domain structure
of glycosyltransferases and glycosidases is shown. These type II membrane proteins consist of an N-terminal cytosolic tail, a transmembrane domain
(TMD), a stem region (these elements are referred to as CTS), and a C-terminal catalytic domain. In the middle and on the right side, design strategies
for creating tailor-made enzymes with the desired catalytic activity and the proper localization in the sec pathway are shown. The combinatorial library
approach involved the combination of large sets of catalytic domains with CTS fragments to fusion proteins, which were then screened for the desired
activity [19,21,22]. Different lengths of the catalytic domains and the CTS fragments were tested (referred to as ‘s’ for short, ‘m’ for medium, ‘l’ for long
and shown exemplarily for one catalytic domain and one CTS). Rational approaches were also used to design these chimeric enzymes [23–25]. The
schematic for the domain architecture and the combinatorial libraries is based on Czlapinski et al. [20] and Nett et al. [26].An essential milestone was achieved in 2006 by intro-
duction of nine synthetic genes and deletion of six
endogenous genes enabling the production of complex
terminally sialylated glycoproteins in P. pastoris [22]. In
the last five years, N-glycosylation  site occupancy has
been increased from 75–85% to 99% [27] and undesired
b-linked mannose residues have been removed by
creating a P. pastoris quadruple knock-out devoid of
all four endogenous b-mannosyl transferases [28].
Furthermore, the production processes using glycoen-
gineered P. pastoris strains have been optimized [29–
31], antibody production in glycoengineered strains
reached the g/l scale [32,33] and glycoengineered strains
have also been established for surface display applications
[34,35].
In addition to human like microbial glycosylation such
heterologous synthetic pathways allow direct control of
the intricate glycosylation process. Thereby, tailor-made
glycoforms of a protein can be produced which can
exhibit moderately differing pharmacodynamics. For
example an antibody expressed in glycoengineered P.
pastoris with a uniform, single glycoform showed
improved antibody-mediated effector functions, com-
pared to mammalian cell culture derived glycoforms with
variable glycosylation patterns [36]. Therefore, better
than nature glycoengineered P. pastoris strains pave thewww.sciencedirect.com way for the creation of synthetic, supernatural glycoform
preparations with altered properties compared to natu-
rally occurring variants.
Synthetic promoters
Efficient transcription is a critical step in gene expression.
Therefore strong and controllable promoters are an essen-
tial tool for high titers in recombinant protein production
[7,37]. In addition to natural promoters there has been a
growing interest in synthetic promoters driving enhanced
expression, improving folding or showing tailor-made
regulatory profiles [37–39]. In P. pastoris, up to 22 g/l
intracellular protein and 15 g/l secreted protein have been
obtained with the most frequently applied, tightly con-
trolled, strong and methanol inducible AOX1 promoter
(PAOX1) [40].
As result, this promoter was the starting point for creating
synthetic variants with increased promoter strength and
altered, methanol free regulation, as the use of toxic and
flammable methanol can cause a considerable safety risk
in industrial processes.
One semi-rational approach to create synthetic PAOX1
variants relied on an in silico analysis for putative con-
served eukaryotic transcription factor binding sites
(TFBS) in PAOX1. Subsequently, the respective shortCurrent Opinion in Biotechnology 2013, 24:1094–1101
1098 Pharmaceutical biotechnology
Figure 3
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Recombinase based self-excisable knockout cassettes for marker regeneration (left side). Increased rates of homologous recombination in a P.
pastoris Dku70 strain (right side). The knockout cassettes consist of a recombinase (Cre or FLP [48,49,50]) and a marker gene flanked by the
respective recombinase recognition sites and are directed to the genome via the 50 and 30 homologous sequences to delete the desired target
sequence. After integration via a double cross-over event, self-excision of the recombinase and the marker gene can be initiated by the expression of
the recombinase from the methanol inducible AOX1 promoter (PAOX1), leaving only the recombinase recognition site in the genome (notably Marx et al.
[49] provided the recombinase transiently on a CEN/ARS plasmid). The initial integration in the genome is dependent on homologous recombination
(HR). Exemplary frequencies of homologous recombination (in %) of the wildtype compared to the Dku70 strain are shown (right side). The length of the
homologous sequence indicates the number of base pairs (bp) added on both sides of the cassette [50]. For 650 bp two different integration loci were
tested, therefore two % values are given.sequence stretches were deleted [41]. These deletion
variants showed both increased and decreased reporter
gene expression levels spanning 6–160% of wildtype
PAOX1 driven expression. Alternative approaches relied
on the systematic deletion of larger adjacent fragments of
almost the entire promoter [42]. Surprisingly, some small
deletions and point mutations resulted in altered regu-
lation as these variants were moderately active when
glucose was depleted, without requiring the inductor
methanol [41]. This derepression effect was further
optimized by combinations of deletions and insertions
of important sequence stretches. Such altered induction
properties now enable the consecutive induction of
coexpressed proteins such as chaperons and the thera-
peutic protein of interest. Putative TFBS of PAOX1 were
also fused to natural core promoter fragments to create
short semi-synthetic variants, which again showed
altered regulation and surpassed the full-length wildtype
promoter in certain applications especially when
multiple copies of the expression cassettes were inte-
grated [41,43]. Also the constitutive promoter of the
glyceraldehyde-3-phosphate dehydrogenase gene (PGAP)
of P. pastoris has been engineered by a random mutagen-
esis approach [44] showing the potential of additional
promoters for expression fine tuning or the generation of
new regulatory circuits. Bio-process strategies for bio-
technologically  relevant enzymes have been improved
by employing these synthetic promoters [41,43,44,45]
and similar effects can be expected for biopharmaceu-
ticals. Furthermore, multiple positive and negative
factors involved in PAOX1 regulation have been identifiedCurrent Opinion in Biotechnology 2013, 24:1094–1101 since this initial semi-rational promoter engineering (see
[40] for a recent review), opening the way for the design
of novel synthetic regulatory circuits for gene expression
and pathway design.
Molecular toolbox for synthetic biology in P.
pastoris
Synthetic biology applications require efficient tools for
strain engineering. For example, the creation of P. pastoris
strains providing a fully humanized glycosylation pattern
necessitated in the first place the development of suitable
genetic strategies to knock out and introduce multiple
genes [46]. Efficient strategies for gene replacements and
marker recycling have now become available for P. pas-
toris. Namely, systems based on new counter selective
markers [47], a Cre/loxP strategy [48,49] and an advanced
flipper cassette application [50] have been reported and
applied. The recombinase based strategies [48,49,50]
allow active excision of the marker gene used in a deletion
cassette and to thereby recycle markers and perform
sequential rounds of deletions. This is achieved by
designing a deletion cassette, in which the marker gene
and the recombinase are flanked by two recombinase
recognition sites and the recombinase is placed under
the tight control of the methanol inducible AOX1 pro-
moter (see Figure 3). Na¨a¨tsaari et al. [50] applied such a
strategy to generate a new platform of P. pastoris expres-
sion strains and Marx et al. [49] boosted riboflavin pro-
duction in P. pastoris by subsequently overexpressing all
six genes of the riboflavin biosynthetic pathway by insert-
ing the strong constitutive GAP promoter upstream ofwww.sciencedirect.com
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Box 1 Milestones and recent accomplishments for
biopharmaceutical production in P. pastoris
(1) FDA GRAS (generally regarded as safe) status in 2006
(Phospholipase C by Diversa Corp., for degumming vegetables
oils for food use).
(2) FDA approved biopharmaceutical production processes in 2009
(Kalbitor by Dyax Corp., a Kallikrein inhibitor) and 2012 (Jetrea by
ThromboGenics NV, for the treatment of vitreomacular traction).
(3) Glycoengineered strains providing humanized, uniform N-glyco-
sylation patterns [22,25].
(4) Synthetic promoters for fine-tuning expression levels [41,42,43].
(5) Efficient strategies for knockouts of multiple genes and over-
expression of entire pathways [48,49,50].
(6) High quality genome sequences [52–54].
(7) Establishment of in silico metabolic models for strain engineer-
ing [55,56,57].these genes. Coupling such approaches with synthetic
promoter variants [41,42,43,44] might support the tran-
scriptional fine tuning of individual enzyme activities of
biosynthetic pathways.
Site specific integration and knock-out strain generation
rely on endogenous homologous recombination. While
in S. cerevisiae HR is working highly efficiently, non-
homologous end joining is the preferred pathway in
most other filamentous fungi and yeasts, including P.
pastoris. HR occurs at less than 1% and up to 30% of all
integration events, depending on the length of the
homologous targeting sequence [50]. For example
during glycoengineering of P. pastoris only 5 out of
460 clones showed the desired gene replacement
[46]. Targeted integration and deletion should become
more efficient in the future by employing a P. pastoris
ku70 deletion strain with increased rates of HR [50]. By
the deletion of a Ku70 homologue, a protein involved in
NHEJ, HR rates of up to 100% were achieved (see
Figure 3). The Dku70 strain did not show genetic
instability, but the growth rates were 10–30% lower
than those of the wildtype (depending on the carbon
source) and the strain showed a decreased survival rate
under UV light. This hints an increased susceptibility to
DNA damage and complementing the wildtype KU70
gene after completion of strain engineering was recom-
mended [50].
In addition to precise deletions, site specific integration,
and marker recycling, new cloning techniques facilitate
the construction of the respective gene expression and
deletion constructs. Efficient in vitro recombination
methods such as Gibson assembly [51] enable flexible
restriction free cloning and library generation allowing
the simple testing of libraries of promoters, artificial or
natural expression enhancers and signal-sequences or
other targeting sequences. Although, bottom up
approaches to design individual parts for P. pastoris strain
reengineering and expression cassette constructions are
ongoing, there is no systematic synthetic biology parts
collection for this yeast so far.
Bioinformatics tools complete the toolbox for synthetic
biology applied in P. pastoris. High-quality genome
sequences [52–54] and metabolic models [55,56,57]
of P. pastoris have recently become available. This com-
prehensive new background knowledge enables research
towards systems wide understanding of the P. pastoris
expression system and provides the basis for reengineer-
ing this host using synthetic parts and pathways to
improve biopharmaceutical production. For example,
recent studies in P. pastoris have hinted an interconnec-
tion of both the carbon metabolism [58] and the cellular
redox state [59] with protein production and secretion.
Thus, similar to S. cerevisiae [60,61], a systems biology
view on secretion coupled with a synergistic use ofwww.sciencedirect.com metabolic engineering and synthetic biology approaches
[62,63] promise coming improvements for biopharmaceu-
tical production by P. pastoris.
Conclusions
Over the last two decades, P. pastoris has been established
as one of the most frequently used expression systems in
both industry and academia. Beside a large number of
various enzymes, many human proteins and biopharma-
ceuticals were also efficiently produced by P. pastoris.
The adaptation of the yeast high-mannose type glycosyl-
ation to the complex humanized glycosylation was a major
achievement and resulted in uniform glycoforms from
microbial production. Synthetic promoter variants with
altered regulatory profiles and expression levels surpassed
their natural counterparts for enzyme production.
Equally, these variants can be used to optimize and
fine-tune the expression of therapeutic proteins. Also
other new key methodologies for synthetic biology such
as efficient gene deletion and assembly strategies, meta-
bolic models and strains with altered recombination
properties have become available. Together with mile-
stones such as the FDA approval, these new tools and
techniques have a high potential to boost the production
of biopharmaceuticals and for efficient metabolic engin-
eering (see Box 1).
Altered and new biosynthetic pathways for posttransla-
tional modifications such as precise glycosylation are
enabling techniques giving access to new therapeutics
with uniform and excellent quality.
Synthetic biology will certainly not only further improve
industrial enzyme production, but also stimulate and
facilitate innovative approaches for biopharmaceutical
production in P. pastoris.Current Opinion in Biotechnology 2013, 24:1094–1101
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